

Becker Transactions Offers 20+ Non-Opioid Pain Management Patents for Sale

PITTSBURGH, PA, UNITED STATES,
September 29, 2026 /

EINPresswire.com/ -- 3V Medical Research Group's patent portfolio addresses applications in non-opioid pain management, viral and bacterial infections, and fungal conditions, as well as copper ion generation for copper ion peptides for skin care.

[Becker Transactions](#) announced that it is offering for sale a portfolio of more than 20 patents covering copper-ion-based solutions intended for use in treating pain, viruses, bacteria, and fungi, as well as for generating copper ions for forming copper ion peptides for skin care, all developed by 3V Medical Research Group with over a decade of R&D and millions invested.



The portfolio covers:

- Base compositions/suspensions, identified in conducted studies as 3VM1000
- Base compositions/ and suspensions in cream form, identified in conducted studies as 3VM1001
- Other delivery mechanisms, such as gels, foams, and transdermal patches
- Manufacturing methods for the compositions/suspensions and various delivery mechanisms
- Methods of treating specified pain, viral, bacterial, fungal, and dermatological conditions

The technology addresses limitations associated with existing products and treatment methods, particularly opioid-based medications. For example, for pain management, the portfolio covers both cream and transdermal patch approaches for administering a low concentration of soluble copper. These drug delivery methodologies allow copper intake to be below recommended daily

allowance (RDA) levels, while avoiding toxicity for internal organs such as gastrointestinal and liver exposure associated with orally delivered or injected medications.

Potential applications include chronic osteoarthritis pain, radiation dermatitis, shingles, post-herpetic neuralgia, and other conditions involving pain and/or skin care.

The portfolio may be of interest to pharmaceutical companies, consumer healthcare companies, medical product manufacturers, and other organizations developing or commercializing copper-ion-based products.



Market Opportunities

The portfolio may address substantial markets, including:

- Chronic osteoarthritis pain affecting hundreds of millions of people worldwide
- Radiation dermatitis associated with radiotherapy treatments
- Shingles and post-herpetic neuralgia, for which treatment options remain limited
- Skin care products based upon copper ion peptides

The U.S. market opportunities for this portfolio include approximately \$3.5 billion annually for knee-pain treatment alone, more than \$210 million annually for radiation dermatitis across cancer-treatment applications, approximately \$200 million annually for shingles and post-herpetic neuralgia, and more than \$100 million annually for copper ion peptide skin care applications.

“Becker Transactions is presenting an extensive patent portfolio covering multiple formulations, delivery formats, manufacturing methods, and therapeutic applications,” said Dean Becker, Chairman of Becker Transactions. “The portfolio offers potential strategic value to companies seeking intellectual property in copper-ion-based healthcare and consumer products.”

About Becker Transactions

Becker Transactions is a world leading patent brokerage firm expertly led by Dean Becker and Olivia Becker, a father daughter team, who bring a family legacy of navigating complex intellectual property transactions. Our team has collectively facilitated over \$11 billion USD in intellectual property transactions. With decades of experience collaborating with inventors, government agencies, top research institutes, universities, and major corporations, we specialize in technology monetization. We excel at identifying essential intellectual property assets and connecting them with strategic buyers seeking competitive advantages.

For additional information regarding the patent portfolio, licensing, or acquisition opportunities, contact:

Olivia N Becker
Becker Transactions
+1 662-338-6617
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/945870383>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.